氟尿嘧啶联合多西他赛或奥沙利铂对胃癌术后辅助化疗的预后影响

Docetaxel or oxaliplatin combined with fluorouracil regimen in postoperative chemotherapy for gastric cancer:An analysis on the prognosis of patients

目的探讨Ⅰ～Ⅲ期胃癌患者术后采用多西他赛或奥沙利铂联合氟尿嘧啶方案治疗的预后。方法选择2010年1月—2011年6月在解放军总医院行手术治疗Ⅰ～Ⅲ期胃癌病例42例,随机将其分为两组:观察组采用多西他赛联合氟尿嘧啶类药物,对照组采用奥沙利铂联合氟尿嘧啶类药物,对两组的无症状生存时间(DFS)、不良反应进行比较。结果观察组的DFS明显高于对照组(P<0.05);与对照组相比,观察组的化疗周期数、手术切缘、化疗不良反应与DFS相关。结论胃癌术后患者采用多西他赛联合氟尿嘧啶类药物治疗DFS明显延长,效果显著。

Objective To compare the two chemotherapy schemes [docetaxel(DTX) or oxaliplatin(OXA) combined with fluorouracil(5-FU)] in the postoperative treatment of gastric cancer(GC) patients,and analyse patient's prognosis. Methods From Jan. 2010 to Jun. 2011 42 cases were diagnosed as stage Ⅰ-Ⅲ GC and divided into two groups randomly:docetaxel(observation) group(21 cases),accepting docetaxel combined with 5-FU regimen,oxaliplatin(control) group(21 cases),accepting oxaliplatin combined with 5-FU regimen;Disease free survival(DFS) and untoward reaction were compared between the two groups. Results DFS of observation group was obviously higher than that of control group(P<0.05);DFS was relevant to chemotherapy periodicity,operation incisal edge,chemotherapy toxin subsidiary reaction in observation group,compared with control group. Conclusion For postoperative gastric cancer patients undergoing chemotherapy,docetaxel combined with 5-FU can achieve good clinical effect,DFS is of obvious prolongation.